Development of the Prostate Cancer Treatment Decision Framework: A Context-Specific Expansion of the Risk-as-Feelings Hypothesis
- PMID: 33332918
- PMCID: PMC8609530
- DOI: 10.1097/NCC.0000000000000918
Development of the Prostate Cancer Treatment Decision Framework: A Context-Specific Expansion of the Risk-as-Feelings Hypothesis
Abstract
Background: Over the past 2 decades, numerous decision-making interventions have been developed to guide the prostate cancer (PrCA) treatment choices of patients and families. These interventions are often supported by economic decision frameworks, which do not account for the role of emotions in treatment decisions. In some instances, emotion-driven decisions can override an individual's cognitive evaluation of a decision, leading to unfavorable outcomes such as decision regret.
Objectives: To produce a Prostate Cancer Treatment Decision Framework based on the Risk-as-Feelings Hypothesis.
Methods: The authors reviewed seminal research in emotion and decision-making in an effort to create a context-specific decision framework.
Results: Five variables, not germane to the Risk-as-Feelings Hypothesis, play prominent roles in PrCA decision-making including age, spirituality, family support, healthcare provider communication, and perception of treatment outcomes. While family support only affects decision outcomes by influencing emotion and cognitive evaluation of a PrCA decision, age, spirituality, and healthcare provider communication can have direct effects on an individual's perception of treatment outcomes.
Conclusions: The Prostate Cancer Treatment Decision Framework combines new variables with older models to explain the PrCA treatment decision-making process and elucidate relationships affecting treatment outcomes and survivors' perceptions of these outcomes. The core premise of this model can be applied to other high-risk health decisions.
Implications for practice: Healthcare providers have the greatest influence on PrCA treatment decision-making. Using a shared decision-making approach, providers should take into account a patient's personal characteristics and values, in addition to clinical presentation, to help patients with treatment decisions.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures

Similar articles
-
'I'm not a chance taker': A mixed methods exploration of factors affecting prostate cancer treatment decision-making.Ethn Health. 2021 Nov;26(8):1143-1162. doi: 10.1080/13557858.2019.1606165. Epub 2019 Apr 15. Ethn Health. 2021. PMID: 30987436 Free PMC article.
-
A qualitative systematic review of internal and external influences on shared decision-making in all health care settings.JBI Libr Syst Rev. 2012;10(58):4633-4646. doi: 10.11124/jbisrir-2012-432. JBI Libr Syst Rev. 2012. PMID: 27820528
-
Prostate cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology.J S C Med Assoc. 2006 Aug;102(7):241-9. J S C Med Assoc. 2006. PMID: 17319238 Review.
-
Perceptions of Urologists About the Conversational Elements Leading to Treatment Decision-Making Among Newly Diagnosed Prostate Cancer Patients.J Cancer Educ. 2017 Sep;32(3):580-588. doi: 10.1007/s13187-016-1025-2. J Cancer Educ. 2017. PMID: 27029194
-
Systematic Review of Decision Aids for Newly Diagnosed Patients with Prostate Cancer Making Treatment Decisions.J Urol. 2015 Nov;194(5):1247-52. doi: 10.1016/j.juro.2015.05.093. Epub 2015 Jun 6. J Urol. 2015. PMID: 26055824
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. - PubMed
-
- American Cancer Society. Key Statistics for Prostate Cancer. 2019. Web site. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html. Accessed July 9, 2019.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous